Product Description
Belinostat is a novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Belinostat)
Mechanisms of Action: HDAC Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Brazil | Chile | Greece | Peru | United States
Approved Indications: None
Company: TopoTarget A/S
Company Location:
Company Founding Year: 2000
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Germany, Hungary, Italy, Korea, Poland, Spain, Taiwan, United States
Active Clinical Trial Count: 6
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Oncology Solid Tumor Unspecified|T-Cell Peripheral Lymphoma
Phase 2: Uveal Melanoma
Phase 1: Adenocarcinoma|Breast Cancer|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04315233 |
CHARGE | P1 |
Recruiting |
Ovarian Cancer|Breast Cancer |
2025-06-01 |
2025-04-23 |
Primary Completion Date|Primary Endpoints|Treatments |
|
NCT04703920 |
UMCC 2020.122 | P1 |
Completed |
Adenocarcinoma|Prostate Cancer|Breast Cancer|Ovarian Cancer|Pancreatic Cancer |
2024-12-01 |
2025-01-24 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT05170334 |
MCC-20955 | P2 |
Active, not recruiting |
Uveal Melanoma |
2025-12-01 |
12% |
2026-04-07 |
Primary Completion Date|Primary Endpoints |
2017-002561-21 |
BELCAP | P3 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2030-10-11 |
2022-03-13 |
Treatments |
|
NCT06072131 |
CRESCENDO | P3 |
Recruiting |
T-Cell Peripheral Lymphoma |
2030-07-01 |
19% |
2024-11-27 |
|
2023-507803-76-00 |
SPI-BEL-301 | P3 |
Recruiting |
T-Cell Peripheral Lymphoma |
2028-03-31 |
2025-05-02 |
Treatments |